307 related articles for article (PubMed ID: 26686343)
21. Long-term evolution of multiple sclerosis disability in the treatment era.
; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
[TBL] [Abstract][Full Text] [Related]
22. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis.
Kim G; Chu R; Yousuf F; Tauhid S; Stazzone L; Houtchens MK; Stankiewicz JM; Severson C; Kimbrough D; Quintana FJ; Chitnis T; Weiner HL; Healy BC; Bakshi R
Int J Neurosci; 2017 Nov; 127(11):971-980. PubMed ID: 28100092
[TBL] [Abstract][Full Text] [Related]
23. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
24. MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis.
Cocozza S; Pontillo G; Lanzillo R; Russo C; Petracca M; Di Stasi M; Paolella C; Vola EA; Criscuolo C; Moccia M; Lamberti A; Monti S; Brescia Morra V; Elefante A; Palma G; Tedeschi E; Brunetti A
Neuroradiology; 2019 Feb; 61(2):155-162. PubMed ID: 30617409
[TBL] [Abstract][Full Text] [Related]
25. Does MRI lesion activity regress in secondary progressive multiple sclerosis?
Zhao Y; Petkau AJ; Traboulsee A; Riddehough A; Li DK
Mult Scler; 2010 Apr; 16(4):434-42. PubMed ID: 20167592
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.
Kappos L; Moeri D; Radue EW; Schoetzau A; Schweikert K; Barkhof F; Miller D; Guttmann CR; Weiner HL; Gasperini C; Filippi M
Lancet; 1999 Mar; 353(9157):964-9. PubMed ID: 10459905
[TBL] [Abstract][Full Text] [Related]
27. Disability in progressive MS is associated with T2 lesion changes.
Ammitzbøll C; Dyrby TB; Lyksborg M; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Garde E; Sørensen PS; Siebner HR; Sellebjerg F
Mult Scler Relat Disord; 2018 Feb; 20():73-77. PubMed ID: 29324249
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
30. Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.
Hardmeier M; Wagenpfeil S; Freitag P; Fisher E; Rudick RA; Kooijmans-Coutinho M; Clanet M; Radue EW; Kappos L;
Arch Neurol; 2003 Dec; 60(12):1736-9. PubMed ID: 14676048
[TBL] [Abstract][Full Text] [Related]
31. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
32. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.
Tomassini V; Paolillo A; Russo P; Giugni E; Prosperini L; Gasperini C; Antonelli G; Bastianello S; Pozzilli C
J Neurol; 2006 Mar; 253(3):287-93. PubMed ID: 16151600
[TBL] [Abstract][Full Text] [Related]
33. The role of global and regional gray matter volume decrease in multiple sclerosis.
Grothe M; Lotze M; Langner S; Dressel A
J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
[TBL] [Abstract][Full Text] [Related]
34. Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.
Leussink VI; Jankovic M; Groth M; Schuh K; Sauerbeck IS; Hoffmann O
Brain Behav; 2024 Jun; 14(6):e3548. PubMed ID: 38841819
[TBL] [Abstract][Full Text] [Related]
35. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
36. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
37. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
38. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
39. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y; Traboulsee A; Petkau AJ; Li D
Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[TBL] [Abstract][Full Text] [Related]
40. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
